BUZZ-Incyte 暂停慢性皮肤病试验后暴跌

Reuters11-19

((自动化翻译由路透提供，请见免责声明 ))

11月19日 - ** 制药商Incyte公司股价盘前下跌11.7%至68美元

** 周一，Incyte公司表示，出于安全考虑，它暂停了一项治疗自发性荨麻疹慢性皮肤病的实验性药物中期试验的注册 (link)。

** INCY还表示，另一种治疗严重瘙痒症（胆汁淤积性瘙痒症）的实验性药物的中期试验数据不支持进一步开发。

** 26家券商中有12家对该股的评级为 "买入 "或更高，13家为 "持有"，1家为 "卖出"；其PT中值为75.06美元--LSEG数据

** 截至上次收盘，该股今年累计上涨 22.6%，而道琼斯美国医疗保健指数的涨幅为 3.5

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484945400?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-19 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484945400","market":"us","top_or_hot":-1,"title":"BUZZ-Incyte 暂停慢性皮肤病试验后暴跌","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    11月19日 - ** 制药商Incyte公司  股价盘前下跌11.7%至68美元</p><p>** 周一，Incyte公司表示，出于安全考虑，它暂停了一项治疗自发性荨麻疹慢性皮肤病的实验性药物中期试验的注册 (link)。</p><p>** INCY还表示，另一种治疗严重瘙痒症（胆汁淤积性瘙痒症）的实验性药物的中期试验数据不支持进一步开发。</p><p>** 26家券商中有12家对该股的评级为 \"买入 \"或更高，13家为 \"持有\"，1家为 \"卖出\"；其PT中值为75.06美元--LSEG数据</p><p>** 截至上次收盘，该股今年累计上涨 22.6%，而道琼斯美国医疗保健指数  的涨幅为 3.5 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Incyte 暂停慢性皮肤病试验后暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Incyte 暂停慢性皮肤病试验后暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 20:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    11月19日 - ** 制药商Incyte公司  股价盘前下跌11.7%至68美元** 周一，Incyte公司表示，出于安全考虑，它暂停了一项治疗自发性荨麻疹慢性皮肤病的实验性药物中期试验的注册 (link)。** INCY还表示，另一种治疗严重瘙痒症（胆汁淤积性瘙痒症）的实验性药物的中期试验数据不支持进一步开发。** 26家券商中有12家对该股...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2484945400","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484945400","pubTimestamp":1732020514,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    11月19日 - ** 制药商Incyte公司  股价盘前下跌11.7%至68美元** 周一，Incyte公司表示，出于安全考虑，它暂停了一项治疗自发性荨麻疹慢性皮肤病的实验性药物中期试验的注册 。** INCY还表示，另一种治疗严重瘙痒症的实验性药物的中期试验数据不支持进一步开发。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4550":"红杉资本持仓","INCY":"因塞特医疗","BK4532":"文艺复兴科技持仓"},"translate_title":"BUZZ-Incyte plunges after suspending chronic skin disease trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    11月19日 - ** 制药商Incyte公司  股价盘前下跌11.7%至68美元** 周一，Incyte公司表示，出于安全考虑，它暂停了一项治疗自发性荨麻疹慢性皮肤病的实验性药物中期试验的注册 (link)。** INCY还表示，另一种治疗严重瘙痒症（胆汁淤积性瘙痒症）的实验性药物的中期试验数据不支持进一步开发。** 26家券商中有12家对该股的评级为 \"买入 \"或更高，13家为 \"持有\"，1家为 \"卖出\"；其PT中值为75.06美元--LSEG数据** 截至上次收盘，该股今年累计上涨 22.6%，而道琼斯美国医疗保健指数  的涨幅为 3.5","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484945400"}